缬沙坦辅助治疗原发性高血压的可行性及安全性

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (30 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical therapeutic effect of Valsartan in the treatment of essential hypertension,the improvement of ambulatory blood pressure and the safety of treatment.Methods Forty-eight patients with primary hypertension admitted to our hospital from October 2015 to October 2017 were selected and divided into observation group and control group according to random number table method,24 cases in each group.The patients in the observation group were given Ammonia Chloride 5 mg/d plus Valsartan 80 mg/d,the control group received Amlodipine 5 mg/d,the two groups were treated for 5 months,the treatment of total effective rate,ambulatory blood pressure monitoring and incidence of adverse reactions were compared detween the two groups.Results The total effective rate of treatment in the observation group (95.83%)was significantly higher than that in the control group (70.83%),and the difference was statistically significant(P<0.05).The 24-hour systolic blood pressure (SBP),24-hour systolic blood pressure variability (SBPV),24-hour diastolic blood pressure (DBP),and 24-hour diastolic blood pressure variability(DBPV)were significantly lower in the observation group than in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the overall incidence of adverse reactions between the two groups(P＞0.05).Conclusion The clinical effect of valsartan in the treatment of essential hypertension is clear,it can positively improve the blood pressure status of patients,and it is safe and worthy of clinical application.

Key words： Valsartan Amlodipine Essential hypertension Adverse reactions Dynamic blood pressure

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZENG Xian-xin

Cite this article:

ZENG Xian-xin. Feasibility and safety of Valsartan in the treatment of essential hypertension[J]. 中国当代医药, 2019, 26(16): 35-37.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I16/35

[1]	蒙钟文.对高血压伴高血脂患者行苯磺酸氨氯地平联用阿托伐他汀钙治疗的效果分析[J].中国医学前沿杂志（电子版），2014，6（5）：75-77.
[2]	效黄汉菊，卢建雄，杨月嫦.缬沙坦联合氨氯地平治疗社区原发性高血压的临床疗及安全性[J].中国老年学杂志，2013，33（9）：2154-2155.
[3]	张敏.缬沙坦联合氨氯地平治疗老年高血压40例临床观察[J].吉林医学，2013，34（12）：4707-4708.
[4]	陈玉环，文轶，林丽莉.缬沙坦联合氨氯地平治疗原发性高血压的疗效及安全性分析[J].齐齐哈尔医学院学报，2014，35（18）：2731-2732．
[5]	王勇，王贤恩，雷玉华.缬沙坦单独治疗与联合氨氯地平治疗原发性高血压的疗效比较[J].中西医结合心脑血管病杂志，2015，23（23）：2525-2527.
[6]	屈友升.脑心通胶囊联用阿托伐他汀治疗老年原发性高血压伴血脂异常的临床疗效观察[J].医学信息，2015，28（21）：11-12．
[7]	陈慧敏，许逸飞.苯磺酸氨氯地平联合阿托伐他汀钙治疗老年高血压伴血脂异常的临床研究[J].中国临床药理学杂志，2016，32（12）：1072-1074.
[8]	易文.缬沙坦联合氨氯地平治疗高血压患者的疗效观察[J].贵阳中医学院学报，2013，35（2）：119-121.
[9]	李志明，唐金娥，欧阳海霞.缬沙坦氨氯地平片对难治性高血压患者血压控制及肾脏保护作用的长期随访研究[J].中国药房，2016，27（17）：2370-2372.
[10]	邓可武，周玉杰，史冬梅，等.缬沙坦/氨氯地平治疗难治性高血压 102 例[J].中国医药导刊，2014，16（7）：1165-1166.
[11]	张亚萍.缬沙坦联合氨氯地平治疗社区老年原发性高血压合并糖尿病的临床观察[J].中国社区医师，2017，33（19）：86-87.
[12]	胡文铭.老年高血压病患者健康干预效果分析[J].保健医学研究与实践，2014，11（3）：54-56.
[13]	郑莉.缬沙坦联合氨氯地平治疗原发性高血压的临床疗效及安全性[J].中国循证心血管医学杂志，2016，8（6）：706-708．
[14]	丁存涛，李静，诸国华，等.老年原发性高血压患者血尿酸与代谢综合征各组分相关关系研究[J].中华老年心脑血管病杂志，2018，21（1）：20-23.
[15]	邓阳生，刘全未，赵增光.原发性高血压患者心血管风险水平分层研究[J].中国现代医学杂志，2016，26（4）：133-137.